A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a ...

First generation PI3Kα-isoform specific inhibitors are limited by significant toxicities due to wild type PI3Kα inhibition, including stomatitis, hyperglycemia and rash.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

First generation PI3Kα-isoform specific inhibitors are limited by significant toxicities due to wild type PI3Kα inhibition, including stomatitis, hyperglycemia and rash.

Ensem Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ETX-636, a Potential Best-In-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader - ETX–636 is ...

Relay Therapeutics announced updated interim clinical data for RLY-2608, an investigational inhibitor of PI3Kα designed for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.

PI3Kα is a well-validated oncology target, but prior inhibitors failed because they exhibited broad inhibition of wild-type PI3Kα and other isoforms with dose-limiting toxicities.

In particular, the company targets treatments for patients with PI3Kα mutations. RLAY’s flagship drug candidate is RLY-2608, with its primary indication being breast cancer.